Modulation of Clopidogrel Pharmacodynamic Response
- 1 December 2008
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 28 (12) , 1423-1424
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy SubjectsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
- Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary SyndromeThe American Journal of Cardiology, 2008
- D-Dimer in ruling out acute aortic dissection: sensitivity is not 100%European Heart Journal, 2008
- Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJournal of Thrombosis and Haemostasis, 2007
- Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patientsPharmacogenetics and Genomics, 2007
- Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjectsJournal of Thrombosis and Haemostasis, 2007
- The Disposition of Prasugrel, a Novel Thienopyridine, in HumansDrug Metabolism and Disposition, 2007
- Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics DifferentlyClinical Pharmacology & Therapeutics, 2007
- Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjectsBlood, 2006
- Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to ClopidogrelArteriosclerosis, Thrombosis, and Vascular Biology, 2006